Bausch Health (BHC)
Sells specialty medicines, medical devices and eye-health products through Bausch + Lomb.
Something off on this page? Send us feedback.
Sells medicines, OTC products and aesthetic devices across gastroenterology, hepatology, neurology and dermatology, while controlling Bausch + Lomb's eye-health business. Its portfolio combines specialty pharmaceuticals and medical devices across international markets.
Develops, manufactures and markets branded, generic and branded-generic medicines, over-the-counter products and aesthetic medical devices. Its therapeutic focus spans gastroenterology, hepatology, neurology and dermatology, with Salix serving as a named specialty-pharma business.
Bausch + Lomb supplies eye-health products through vision-care, surgical and ophthalmic businesses; Bausch Health retains control of the separately traded subsidiary. International, Diversified and Solta Medical complement the parent's operating structure.
Products are marketed directly or indirectly in more than 90 countries and regions. The business combines pharmaceutical and medical-device operations, while control of Bausch + Lomb remains a defining structural feature.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Jan 7, 2026 | Truist Financial | Target | Target: $7 | Target: $8 |
| Dec 8, 2025 | Barclays | Target | Target: — | Target: $8 |
| Feb 6, 2025 | Jefferies | Downgrade |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $1.83B · Total debt $20.78B · Total assets $24.79B · Shareholders' equity −$1.77B
- Revenue
- $2.85B
- Operating income
- $775.0M
- Net income
- $258.0M
No dividends on record.
| Institutions | 63.99% | 239.32M shares | |
|---|---|---|---|
| 243 holders · as of Jun 30, 2026 | |||
| Insiders | 22.48% | 84.08M shares | |
| 21 holders · as of Aug 20, 2026 | |||
| Other | 13.53% | 50.59M shares | |
| remainder | |||
373.99M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Paulson & Co. Inc.Institution | 19.59% | 73.26M | as of Jun 30, 2026 |
Alex MerueloInsider | 9.83% | 36.76M | filed Apr 7, 2025 |
Goldentree Asset Management LPInstitution | 9.27% | 34.67M | as of Jun 30, 2026 |
Schedule 13dInsider | 5.60% | 20.94M | filed Jul 27, 2020 |
Steven A. TananbaumInsider | 5.28% | 19.75M | filed Feb 13, 2023 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 19, 2026 | Aimee J. Lenar | officer: President, US Pharma | −36,827 | $7.03 |
| May 19, 2026 | Frank D. Lee | director | −24,456 | $5.43 |
| Mar 3, 2026 | Seana Carson | officer: EVP, General Counsel | −4,420 | $5.77 |
| Mar 2, 2026 | Seana Carson | officer: EVP, General Counsel | −6,856 | $5.78 |
| Feb 27, 2026 | Seana Carson | officer: EVP, General Counsel | −8,388 | $5.95 |
- Alcon
Eye-health rival across contacts, intraocular lenses and surgery
- CooperCompanies
Contact-lens rival in spherical, toric and multifocal lenses
- Johnson & Johnson
Vision-care rival in contact lenses and ophthalmic surgery
- AbbVie
Ocular-health and aesthetics rival through the Allergan portfolio
- Teva (ADR)
Branded and generic pharmaceutical rival in international markets
- Ironwood Pharmaceuticals
Direct GI rival in adult IBS-C and chronic idiopathic constipation
- InMode
Energy-based aesthetics rival in skin rejuvenation and contouring
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Bausch Health | $5.73 | +1.51% | $2.11B | — | 1.3 | 0.2 | +11.2% |
| Alcon | $65.41 | +0.83% | $31.64B | 49.9 | 17.2 | 2.9 | +7.5% |
| CooperCompanies | $55.06 | +1.73% | $10.56B | 18.5 | 12.0 | 2.5 | +0.6% |
| Johnson & Johnson | $269.57 | +0.04% | $649.40B | 31.2 | 22.7 | 6.6 | +6.6% |
| AbbVie | $265.68 | +0.45% | $467.37B | 74.5 | 17.5 | 7.3 | +10.2% |
| Teva (ADR) | $39.54 | −1.30% | $46.66B | 66.8 | 14.1 | 2.7 | −0.8% |
| Ironwood Pharmaceuticals | $4.55 | +3.13% | $725.9M | 5.7 | 3.7 | 1.9 | +32.6% |
| InMode | $14.49 | −0.09% | $833.5M | 11.8 | 11.0 | 2.2 | −0.0% |
| Median | 31.2 | 14.1 | 2.7 | +6.6% |